Cargando…

Severe COVID-19 and preexisting hypertension: a matter of age?

Detalles Bibliográficos
Autores principales:	Yamazaki, Osamu, Shibata, Shigeru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283815/ https://www.ncbi.nlm.nih.gov/pubmed/35840751 http://dx.doi.org/10.1038/s41440-022-00978-1

Ejemplares similares

COVID-19 in Africa: preexisting immunity and HIV
por: Snyman, Jumari, et al.
Publicado: (2021)

Preexisting prediabetes and the severity of COVID-19
por: Sathish, Thirunavukkarasu, et al.
Publicado: (2021)

How to deal with hypertension in the COVID-19 era—the impact “ON” and “OF” hypertension
por: Ishida, Mari
Publicado: (2021)

Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?
por: Zhang, Chao, et al.
Publicado: (2020)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

Resistant hypertension and COVID-19: tip of the iceberg?
por: Tadic, Marijana, et al.
Publicado: (2021)

A pandemic is no private matter: the COVID-19 vaccine mandate in Austria
por: Druml, Christiane, et al.
Publicado: (2022)

The association of preexisting severe asthma with COVID-19 outcomes
por: Terry, Paul D., et al.
Publicado: (2023)

COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society
por: Clark, Christopher E., et al.
Publicado: (2021)

Azithromycin for severe COVID-19
por: Oldenburg, Catherine E, et al.
Publicado: (2020)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Quantifying the RSV immunity debt following COVID-19: a public health matter
por: Billard, Marie-Noëlle, et al.
Publicado: (2022)

Sulfasalazine: a risk factor for severe COVID-19?
por: Konig, Maximilian F, et al.
Publicado: (2022)

The COVID-19 vaccines rush: participatory community engagement matters more than ever
por: Burgess, Rochelle Ann, et al.
Publicado: (2021)

From Preproduction to Coproduction: COVID-19, whiteness, and making black mental health matter
por: King, Colin, et al.
Publicado: (2021)

Observational research on severe COVID-19 in diabetes
por: Stehouwer, Coen D A
Publicado: (2021)

Anxiety and hypertension in the COVID-19 era: how is the central autonomic network linked?
por: Nagai, Michiaki, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension
por: Azushima, Kengo, et al.
Publicado: (2022)

From routine data collection to policy design: sex and gender both matter in COVID-19
por: Evagora-Campbell, Mireille, et al.
Publicado: (2021)

COVID-19 severity and obesity: are MAIT cells a factor?
por: McCarthy, Cormac, et al.
Publicado: (2021)

The effects of antihypertensive medications on severity and outcomes of COVID19
por: Agirbasli, Mehmet
Publicado: (2022)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Epidemiology of severe COVID-19 from South Africa
por: Madhi, Shabir A, et al.
Publicado: (2021)

Are women with asthma at increased risk for severe COVID-19?
por: Fernando, Mario, et al.
Publicado: (2021)

Severe COVID-19 pneumonitis and timing of birth in women
por: Calvert, Clara, et al.
Publicado: (2023)

COVID-19 vaccines in the age of the delta variant
por: Wheatley, Adam K, et al.
Publicado: (2022)

Age and frailty in COVID-19 vaccine development
por: Andrew, Melissa K, et al.
Publicado: (2021)

Is precision medicine relevant in the age of COVID-19?
por: Zhou, Amy, et al.
Publicado: (2021)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Who, what, and when—effective therapy for severe COVID-19
por: Kelmenson, Daniel A, et al.
Publicado: (2022)

Severe mental illness and European COVID-19 vaccination strategies
por: De Picker, Livia J, et al.
Publicado: (2021)

Mounting evidence of impaired viral control in severe COVID-19
por: Bermejo-Martin, Jesus F, et al.
Publicado: (2021)

Preexisting comorbidities shape the immune response associated with severe COVID-19
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes
por: Kruglikov, Ilja L., et al.
Publicado: (2021)

Baricitinib for patients with severe COVID-19—time to change the standard of care?
por: Supady, Alexander, et al.
Publicado: (2022)

Stimulating severe COVID-19: the potential role of GM-CSF antagonism
por: Leavis, Helen L, et al.
Publicado: (2022)

Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?
por: Zhang, Shen-Ying, et al.
Publicado: (2020)

Treatment for severe acute respiratory distress syndrome from COVID-19
por: Matthay, Michael A, et al.
Publicado: (2020)

Will helminth co-infection modulate COVID-19 severity in endemic regions?
por: Bradbury, Richard S., et al.
Publicado: (2020)

Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes
por: Leshem, Eyal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1c98cbid5oqrgv4cshvm76m1eo